New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related 
macular degeneration, central retinal vein occlusion, diabetic macular edema, 
and choroidal neovascularization secondary to pathologic myopia

Robert Rejdak; Małgorzata Szkaradek; Wesam Taslaq; Jakub Kałużny; Paweł Grieb; Anselm Jünemann

eISSN: 2719-3209
ISSN: 0023-2157

Klinika Oczna / Acta Ophthalmologica Polonica

Current issue Archive Videos Articles in press About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

4/2012
vol. 114

Send email

Copy url:

abstract:

Review article

New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia

Robert Rejdak

^{1, 2}

,

Małgorzata Szkaradek

²

,

Wesam Taslaq

²

,

Jakub J. Kałużny

³

,

Paweł Grieb

⁴

,

Anselm G. M. Jünemann

⁵

Klinika Okulistyki Ogólnej, Katedra Okulistyki Uniwersytetu Medycznego w Lublinie
Oddział Okulistyki Wojewódzkiego Szpitala Specjalistycznego im. F. Chopina w Rzeszowie
Katedra Zdrowia Publicznego Collegium Medicum w Bydgoszczy Uniwersytetu Mikołaja Kopernika w Toruniu
Zakład Farmakologii Doświadczalnej Instytutu Medycyny Doświadczalnej i Klinicznej Polskiej Akademii Nauk w Warszawie
Klinik für Augenheilkunde, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen – Nürnberg, Erlangen

Online publish date: 2012/12/12

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Rejdak R, Szkaradek M, Taslaq W, Kałużny JJ, Grieb P, Jünemann AG. New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related 
macular degeneration, central retinal vein occlusion, diabetic macular edema, 
and choroidal neovascularization secondary to pathologic myopia. Klinika Oczna / Acta Ophthalmologica Polonica. 2012;114(4):308-310.

APA

Rejdak, R., Szkaradek, M., Taslaq, W., Kałużny, J. J., Grieb, P.,  & Jünemann, A. G. (2012). New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related 
macular degeneration, central retinal vein occlusion, diabetic macular edema, 
and choroidal neovascularization secondary to pathologic myopia. Klinika Oczna / Acta Ophthalmologica Polonica, 114(4), 308-310.

Chicago

Rejdak, Robert, Małgorzata Szkaradek, Wesam Taslaq, Jakub J Kałużny, Paweł Grieb,  and Anselm G Jünemann. 2012. "New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related 
macular degeneration, central retinal vein occlusion, diabetic macular edema, 
and choroidal neovascularization secondary to pathologic myopia". Klinika Oczna / Acta Ophthalmologica Polonica 114 (4): 308-310.

Harvard

Rejdak, R., Szkaradek, M., Taslaq, W., Kałużny, J., Grieb, P.,  and Jünemann, A. (2012). New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related 
macular degeneration, central retinal vein occlusion, diabetic macular edema, 
and choroidal neovascularization secondary to pathologic myopia. Klinika Oczna / Acta Ophthalmologica Polonica, 114(4), pp.308-310.

MLA

Rejdak, Robert et al. "New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related 
macular degeneration, central retinal vein occlusion, diabetic macular edema, 
and choroidal neovascularization secondary to pathologic myopia." Klinika Oczna / Acta Ophthalmologica Polonica, vol. 114, no. 4, 2012, pp. 308-310.

Vancouver

Rejdak R, Szkaradek M, Taslaq W, Kałużny J, Grieb P, Jünemann A. New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related 
macular degeneration, central retinal vein occlusion, diabetic macular edema, 
and choroidal neovascularization secondary to pathologic myopia. Klinika Oczna / Acta Ophthalmologica Polonica. 2012;114(4):308-310.

Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of choroidal and retinal neovascularization. Anti-VEGF therapy changed the standard-of-care for ocular disease with neovascularisation. This article presents one promising new drug – VEGF Trap-Eye – and results of clinical trials evaluating its efficacy in the treatment of wet age-related macular degeneration, central retinal vain occlusion, diabetic macular edema and choroidal neovascularization secondary to pathologic myopia.

keywords:

New drug VEGF Trap-Eye – Eylea – and its use in the treatment of age-related macular degeneration, central retinal vein occlusion, diabetic macular edema, and choroidal neovascularization secondary to pathologic myopia

Robert Rejdak 1, 2 , Małgorzata Szkaradek 2 , Wesam Taslaq 2 , Jakub J. Kałużny 3 , Paweł Grieb 4 , Anselm G. M. Jünemann 5

vascular endothelial growth factor, VEGF Trap-Eye, Eylea, neovascularization

Robert Rejdak

^{1, 2}

,

Małgorzata Szkaradek

²

,

Wesam Taslaq

²

,

Jakub J. Kałużny

³

,

Paweł Grieb

⁴

,

Anselm G. M. Jünemann

⁵